Iksuda Therapeutics to Present Phase 1 Data for HER2-Targeting ADC IKS014 at ESMO 2025, Announces Results from Dose Escalation Study

Reuters10-14

Iksuda <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present Phase 1 Data for HER2-Targeting ADC IKS014 at ESMO 2025, Announces Results from Dose Escalation Study

Iksuda Therapeutics, a portfolio company of IP Group plc, has announced that new data from its Phase 1 study of IKS014, a HER2-targeting antibody drug conjugate $(ADC)$, will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, scheduled for October 17-21, 2025. The results, from the dose escalation portion of the trial conducted in Australia, will be shared during a poster session on October 19, 2025. The Phase 1 study is evaluating IKS014 in patients with advanced HER2-positive solid tumors, focusing on establishing the maximum-tolerated dose and/or recommended Phase 2 dose, as well as assessing initial safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575595298?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575595298","market":"nz","top_or_hot":-1,"title":"Iksuda Therapeutics to Present Phase 1 Data for HER2-Targeting ADC IKS014 at ESMO 2025, Announces Results from Dose Escalation Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Iksuda <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Phase 1 Data for HER2-Targeting ADC IKS014 at ESMO 2025, Announces Results from Dose Escalation Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Iksuda Therapeutics, a portfolio company of IP Group plc, has announced that new data from its Phase 1 study of IKS014, a HER2-targeting antibody drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, scheduled for October 17-21, 2025. The results, from the dose escalation portion of the trial conducted in Australia, will be shared during a poster session on October 19, 2025. The Phase 1 study is evaluating IKS014 in patients with advanced HER2-positive solid tumors, focusing on establishing the maximum-tolerated dose and/or recommended Phase 2 dose, as well as assessing initial safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iksuda Therapeutics to Present Phase 1 Data for HER2-Targeting ADC IKS014 at ESMO 2025, Announces Results from Dose Escalation Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIksuda Therapeutics to Present Phase 1 Data for HER2-Targeting ADC IKS014 at ESMO 2025, Announces Results from Dose Escalation Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 17:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Iksuda <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Phase 1 Data for HER2-Targeting ADC IKS014 at ESMO 2025, Announces Results from Dose Escalation Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Iksuda Therapeutics, a portfolio company of IP Group plc, has announced that new data from its Phase 1 study of IKS014, a HER2-targeting antibody drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, scheduled for October 17-21, 2025. The results, from the dose escalation portion of the trial conducted in Australia, will be shared during a poster session on October 19, 2025. The Phase 1 study is evaluating IKS014 in patients with advanced HER2-positive solid tumors, focusing on establishing the maximum-tolerated dose and/or recommended Phase 2 dose, as well as assessing initial safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPO.UK","symbol_name":"IP GROUP","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDLbnz3Bv:1","article_id":"2575595298","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575595298","pubTimestamp":1760433978,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Iksuda Therapeutics to Present Phase 1 Data for HER2-Targeting ADC IKS014 at ESMO 2025, Announces Results from Dose Escalation Study. Iksuda Therapeutics, a portfolio company of IP Group plc, has announced that new data from its Phase 1 study of IKS014, a HER2-targeting antibody drug conjugate , will be presented at the upcoming European Society for Medical Oncology  Congress in Berlin, Germany, scheduled for October 17-21, 2025. The results, from the dose escalation portion of the trial conducted in Australia, will be shared during a poster session on October 19, 2025. The Phase 1 study is evaluating IKS014 in patients with advanced HER2-positive solid tumors, focusing on establishing the maximum-tolerated dose and/or recommended Phase 2 dose, as well as assessing initial safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPO.UK":"IP GROUP","BK5078":"资产管理与托管银行"},"translate_title":"Iksuda Therapeutics将在ESMO 2025上展示HER2靶向ADC IKS014的1期数据，并公布剂量递增研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPO.UK":0.9},"content_text":"Iksuda Therapeutics to Present Phase 1 Data for HER2-Targeting ADC IKS014 at ESMO 2025, Announces Results from Dose Escalation Study\n    \n\n        Iksuda Therapeutics, a portfolio company of IP Group plc, has announced that new data from its Phase 1 study of IKS014, a HER2-targeting antibody drug conjugate $(ADC)$, will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, scheduled for October 17-21, 2025. The results, from the dose escalation portion of the trial conducted in Australia, will be shared during a poster session on October 19, 2025. The Phase 1 study is evaluating IKS014 in patients with advanced HER2-positive solid tumors, focusing on establishing the maximum-tolerated dose and/or recommended Phase 2 dose, as well as assessing initial safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575595298","isCrawlerRequest":true}